Bank of New York Mellon Corp Buys Shares of 17,233 Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• The Bank of New York Mellon Corp acquired 17,233 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE), valued at approximately $190,000, indicating growing interest from institutional investors.
• Research firms have rated Maze Therapeutics with multiple buy ratings, with an average target price of $25.60, reflecting a positive outlook for the company's stock performance.
• Maze Therapeutics reported earnings per share of ($1.15), which fell short of the consensus estimate, highlighting ongoing challenges despite a robust investment interest.

Bank of New York Mellon Corp bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,233 shares of the company's stock, valued at approximately $190,000.

Separately, General Catalyst Group Management LLC purchased a new position in shares of Maze Therapeutics during the first quarter worth about $11,405,000.

Maze Therapeutics Price Performance

NASDAQ:MAZE traded down $0.18 during midday trading on Friday, reaching $13.14. The stock had a trading volume of 72,288 shares, compared to its average volume of 155,301. The business's fifty day simple moving average is $13.90. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Wall Street Analyst Weigh In

A number of research firms have weighed in on MAZE. HC Wainwright initiated coverage on Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Wedbush started coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.